What are the most common side effects of orforglipron?

Digestive effects are common. In the pooled weight-management trials, nausea occurred in 26–35% of Foundayo-treated participants versus 10% with placebo, depending on dose. Constipation, diarrhea, vomiting, indigestion, abdominal pain, headache and hair loss were also reported. The table below gives the individual dose groups and study context. Nausea, vomiting and diarrhea were more frequent during dose escalation and decreased over time, but not on a guaranteed schedule for every person.

Is orforglipron easier on the stomach than injectable GLP-1s?

A pill is not automatically easier on the stomach: Foundayo can cause substantial gastrointestinal effects. However, rates from separate trials do not establish equal tolerability with injectable semaglutide or tirzepatide. The formulation, dose, population and study design matter. Follow the prescribed escalation schedule and discuss persistent symptoms rather than choosing a drug solely by whether it is injected or swallowed.

Does orforglipron cause hair loss?

Hair loss was reported in 4–5% of the Foundayo dose groups versus 2% with placebo in pooled weight-management trials. The label associates these reports with weight reduction, but does not establish that every case is telogen effluvium or guarantee reversal after weight stabilizes. Persistent, patchy or substantial hair loss deserves assessment for other causes; do not start iron supplements without an identified need.

How long do orforglipron side effects last?

The trials found that nausea, vomiting and diarrhea were more frequent during escalation and decreased over time. They do not establish a universal one-to-two-week resolution time. Contact your prescriber if symptoms persist, interfere with eating or daily life, or recur after an increase. Severe pain, persistent vomiting, inability to keep fluids down or reduced urination should not wait for a routine follow-up.

Who should not take orforglipron?

Foundayo is contraindicated with personal or family MTC, MEN 2, or a prior serious allergic reaction to orforglipron or its ingredients. It is not recommended with severe gastroparesis, severe hepatic impairment or while nursing, and should be discontinued when pregnancy is recognized. A history of pancreatitis is important to discuss but is not itself listed as a formal contraindication. Review other medicines, gallbladder history and diabetic retinopathy with the prescriber.

Can orforglipron cause pancreatitis?

Acute pancreatitis has been reported with Foundayo. In the pooled trials, six events were confirmed in six treated patients versus two events in one placebo patient; these are event and patient counts, not percentages. Persistent or severe abdominal pain, sometimes extending to the back and with or without nausea or vomiting, needs prompt medical assessment. Stop Foundayo if pancreatitis is suspected; do not wait for a taper.

How do I manage nausea on orforglipron?

Smaller meals, stopping when comfortably full and avoiding personal food triggers can help with mild nausea. Sip fluids, following any fluid restriction you have been given. Foundayo can be taken with or without food; swallow the tablet whole and do not take more than one tablet per day. Ask the prescriber about ongoing symptoms and escalation before changing doses or adding anti-nausea medicines. Severe symptoms need assessment rather than simply eating less.

Weight LossUS prescribing information

Orforglipron (Foundayo) Side Effects: What to Expect

By the Peptide Dossier Editorial TeamUpdated September 12, 2026How we source

Orforglipron, sold as Foundayo, is a once-daily oral GLP-1 medicine for weight management. Digestive symptoms are common, but the pill has its own trial results, thyroid-warning context and medication interactions. Here are the dose-specific frequencies, practical questions and warning signs to discuss with your prescriber.

Orforglipron at a Glance

Foundayo was approved in the US on April 1, 2026, with a reduced-calorie diet and increased physical activity for adults with obesity or overweight plus at least one weight-related condition. It is a small-molecule, non-peptide GLP-1 receptor agonist taken once daily, with or without food. It was not the first oral GLP-1 approved for weight management: Wegovy tablets were approved in December 2025. FDA Foundayo announcement; Wegovy tablet approval announcement.

GLP-1 activity helps explain overlapping digestive effects, but not identical risks across products. The pill format does not eliminate gastrointestinal symptoms. Our GLP-1 side effects guide provides broader context. For background on the drug itself, see our orforglipron overview and the Foundayo guide.

Common Side Effects

Nausea, constipation, diarrhea and vomiting are prominent in the trial data. The list below summarizes common concerns; the following table supplies the actual rates and includes additional reactions listed in the label.

Nausea — the most frequent individual reaction in the table
Constipation and diarrhea — different symptoms that need different management
Vomiting — persistent vomiting can lead to dehydration and needs assessment
Indigestion, abdominal pain, bloating and reflux — reported separately or as grouped terms in the label
Headache and fatigue — included among common reactions, without a guaranteed onset or duration
Hair loss — associated with weight reduction in the trials, not proof of one mechanism or guaranteed reversibility

Our pages on managing GLP-1 nausea and constipation on GLP-1s offer related symptom discussions. Their product-specific dosing instructions should not be transferred to Foundayo.

How Common Are These Effects?

The July 2026 US label pools two randomized, double-blind, placebo-controlled weight-management trials in adults with obesity or overweight, with or without type 2 diabetes. Treatment lasted up to 72 weeks, followed by two weeks off drug. The 3,155 treated participants received an investigational formulation; the label presents its results using equivalent marketed Foundayo doses. These are trial rates, not predictions for an individual or valid head-to-head comparisons with other drugs.

Common adverse reactions, pooled Trials 1 and 2: up to 72 weeks plus two-week off-drug follow-up. July 2026 label, Table 1.
Adverse reaction	Placebo N=1,576	5.5 mg daily N=1,051	9 mg daily N=1,055	17.2 mg daily N=1,049
Nausea	10%	26%	34%	35%
Constipation	9%	20%	27%	24%
Diarrhea	11%	21%	23%	25%
Vomiting	4%	13%	21%	24%
Indigestion (dyspepsia)	4%	12%	16%	13%
Abdominal pain*	7%	13%	14%	14%
Headache	7%	8%	9%	9%
Abdominal distension	3%	7%	9%	8%
Fatigue*	4%	6%	7%	9%
Burping (eructation)	1%	6%	8%	8%
Gastroesophageal reflux disease	2%	6%	6%	7%
Flatulence	2%	5%	6%	6%
Hair loss*	2%	4%	4%	5%

*Grouped terms include related adverse-reaction terms. The table lists reactions reaching at least 5% in a treated group and occurring more often than placebo. Foundayo prescribing information, section 6.1.

Any gastrointestinal adverse reaction occurred in 60%, 68% and 69% of the respective Foundayo groups versus 37% with placebo. Discontinuation because of any adverse reaction occurred in 6%, 9% and 10% versus 3%. Nausea, vomiting and diarrhea were more frequent during escalation and decreased over time; the label does not promise resolution within one or two weeks.

The Thyroid Boxed Warning

Foundayo carries a boxed warning for thyroid C-cell tumors. Unlike GLP-1 agonists that are active in rodents and produced C-cell tumors, orforglipron is not pharmacologically active in rats or mice and did not produce tumors in those animals. It is active at the human receptor; the human relevance of the rodent GLP-1 findings remains undetermined. Foundayo is contraindicated with a personal or family history of medullary thyroid carcinoma (MTC) or MEN 2. Boxed warning and section 5.1.

Report a neck lump, persistent hoarseness, trouble swallowing or shortness of breath for assessment. Routine calcitonin testing or thyroid ultrasound has uncertain value for screening everyone taking Foundayo. Our semaglutide and thyroid cancer explainer provides related background, but the exact drug-specific findings above matter.

Serious but Less Common Risks

The label distinguishes adverse reactions observed with Foundayo from broader GLP-1 postmarketing reports. The latter cannot reliably establish a frequency or prove causation for Foundayo. Important problems to recognize include:

Pancreatitis: Persistent or severe abdominal pain, sometimes reaching the back, with or without nausea or vomiting. Stop Foundayo if suspected and seek prompt assessment. Pooled trials recorded six events in six treated patients versus two events in one placebo patient.
Gallbladder disease: Right upper abdominal pain, fever or jaundice needs assessment. Gallstones occurred in 1% versus 0.7% with placebo; acute cholecystitis in 0.4% versus 0.3% in the pooled trials.
Hypoglycemia: It can occur, including without diabetes; risk is higher with insulin or sulfonylureas. Ask for a glucose-monitoring and treatment plan and any needed prescriber-led adjustment of those medicines.
Kidney injury and dehydration: Ongoing vomiting or diarrhea, reduced urination or inability to keep fluids down needs prompt care. Acute kidney injury was reported in 0.2% versus 0.05% with placebo in the pooled trials.
Eye concerns: Rapid glucose improvement can temporarily worsen diabetic retinopathy. Existing retinopathy needs monitoring; Foundayo has not been studied in retinopathy or macular edema needing acute treatment.
Severe digestive symptoms: Persistent vomiting, severe abdominal swelling or inability to pass stool or gas needs assessment. Do not treat possible obstruction by simply adding fiber.
Serious allergy: Stop Foundayo and seek medical care for suspected hypersensitivity. Breathing difficulty, throat or tongue swelling, or collapse is an emergency: call 911.
Procedures and anesthesia: Tell the procedure team you take Foundayo. Delayed gastric emptying can leave stomach contents despite fasting; do not invent your own preoperative hold or fasting schedule.

These percentages refer to the pooled trials described above, not annual risks. Prescribing information, sections 5 and 6.1–6.2.

Who needs a different plan: a prior serious allergic reaction to orforglipron or its ingredients is a contraindication, alongside MTC/MEN 2. Severe gastroparesis, severe hepatic impairment and nursing are situations where Foundayo is not recommended. Discontinue when pregnancy is recognized. A pancreatitis history is important to discuss, but is not itself listed as a formal contraindication. Do not combine Foundayo with another GLP-1 receptor agonist. Sections 1, 4 and 8.

Medication review matters: strong CYP3A4 inhibitors can raise exposure; the label limits Foundayo to 9 mg daily with these drugs and says to avoid strong inhibitors that also inhibit OATP1B, such as ritonavir. Avoid strong CYP3A4 inducers; moderate inducers need effectiveness monitoring. Simvastatin must not exceed 20 mg daily with Foundayo. Have the prescriber or pharmacist resolve these interactions rather than adjusting either medicine yourself. Section 7.

Oral contraception: switch to a non-oral method or add a barrier method for 30 days after starting Foundayo and for 30 days after each dose increase. This is a product-specific precaution about potentially altered oral absorption, not a claim that every hormonal method is affected. Discuss the choice with your clinician. Sections 7.3 and 8.3.

For a fuller class picture, see GLP-1 contraindications and who should not take a GLP-1.

Orforglipron vs Injectable GLP-1 Side Effects

A pill is not automatically gentler, but overlapping side effects are not proof of equal tolerability. Comparing percentages from unrelated trials can be misleading. ACHIEVE-3 directly compared orforglipron with oral semaglutide in adults with type 2 diabetes; that comparator should not be relabeled injectable semaglutide or tirzepatide. ACHIEVE-3 primary report.

Foundayo avoids needles and can be taken with or without food. Convenience, symptom tolerance, interactions and the relevant indication all matter. Compare options in which GLP-1 is best for weight loss, Foundayo vs Wegovy, and Foundayo vs Zepbound.

How to Manage Side Effects

For mild digestive symptoms, practical adjustments may help. These suggestions come from GLP-1 expert consensus, not a Foundayo-specific randomized management trial:

Discuss escalation: Follow the prescribed schedule. If symptoms persist, ask the prescriber about the next increase instead of changing doses yourself.
Eat smaller portions: Eat slowly, stop when comfortably full and avoid lying down immediately after meals.
Identify triggers: Bland, lower-fat meals may be easier to tolerate; keep track of foods that worsen your symptoms.
Sip fluids: Maintain hydration while respecting any fluid restriction. Inability to keep fluids down or reduced urination needs assessment.
Address mild constipation: Adequate fiber, fluids and light activity may help. Severe pain, swelling, vomiting or inability to pass gas calls for assessment, not more fiber.
Assess hair loss separately: Discuss substantial or persistent shedding and possible nutritional or other causes. Iron is not a routine preventive treatment without an identified need.

Multidisciplinary expert consensus, Table 2. Foundayo can be taken with or without food; swallow the tablet whole and take no more than one tablet per day. Ask your pharmacist before adding symptom medicines. Prescribing information, section 2.

Our GLP-1 tapering guide discusses longer-term discontinuation planning, but Foundayo does not require a mandatory taper. Suspected pancreatitis, serious allergy or recognized pregnancy calls for stopping as directed in the label, not delaying to taper. Discuss a replacement treatment plan with the prescriber.

When to Contact a Doctor

Call 911 for breathing difficulty, throat or tongue swelling, collapse or another life-threatening reaction. Otherwise, seek prompt assessment for:

Severe or persistent abdominal pain, especially radiating to the back (possible pancreatitis)
Signs of a thyroid tumor: a neck lump, hoarseness, or trouble swallowing
Right upper abdominal pain with fever or yellowing of the skin or eyes (possible gallbladder problem)
Symptoms of severe dehydration or reduced urination
Persistent vomiting or inability to keep fluids down
New or worsening vision symptoms, especially with diabetic retinopathy

Bottom Line

Foundayo offers a once-daily, needle-free weight-management option with no food restriction for dosing. Gastrointestinal effects are common, and trial rates vary by dose. Symptoms often decrease over time, but there is no guaranteed recovery timetable or proof that a pill is better tolerated than an injection. The product-specific thyroid warning, interactions, contraception precautions and warning signs are part of choosing and using it well.

This guide is for education only and is not medical advice. Orforglipron is a prescription medication; make routine treatment decisions with a licensed clinician. Emergency symptoms should not wait for a routine appointment.